NEWS COMMENTARY

Teladoc Health acquires Livongo Health for $18.5 billion

Published:
August 05, 2020
Services:
Consumer
Activities:
Acquisition
by Danielle Bradnan
Truly disruptive

This is an enormous deal in terms of both money and the market context of telehealth. It brings juggernaut digital therapeutic Livongo Health into the fold of Teladoc, critically augmenting the more traditional video conferencing approach where Teladoc has been a market leader with remote monitoring and mHealth capabilities. This is important for bolstering Teladoc against the video conferencing-based telehealth bubble that is likely to burst in the U.S. due to a renewed lack of reimbursement and all but ensures Teladoc Health's primacy in the telehealth space. Clients looking to compete in the telehealth space need to move now, focusing on acquisition targets that lean into the remote monitoring and mHealth capabilities of telehealth.

For the original news article, click here .


Further Reading

Agrifood and Health 2020 Year in Review: Prevention and Personalization in Health

Analyst Insight | December 21, 2020

This insight is part of the Lux Agrifood and Health Team's Year in Review series examining the highlights and key developments of 2020. For an overview of the other themes in the Emerging Ecosystems in Agrifood and Health program, see our insights on The Food Company of 2050, Doing More with Less, ... Not part of subscription

COVID-19 exacerbated the symptoms of an already-sick health system, and long-tail symptoms are pointing the way to fixing it

Analyst Insight | June 01, 2021

It's been a little over a year since the worst pandemic in a century closed businesses and homes to the outside world. Now, with the hope of multiple vaccines and both countries and companies beginning to advance through reopening processes, it's time to start laying the groundwork for future ... Not part of subscription

The continuous glucose monitoring pricing dilemma for Type 2 diabetes

Case Study | May 14, 2021

Kaiser Health News recently published an article calling into question the efficacy of minimally invasive continuous glucose monitoring (CGM) solutions for non‑insulin‑treated Type 2 diabetic patients. These CGM solutions are inserted under the skin and typically measure interstitial glucose levels... Not part of subscription